VALSTAR PRESERVATIVE FREE
LOE Approachingvalrubicin
NDAINTRAVESICALSOLUTIONPriority Review
Approved
Sep 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Valstar Preservative Free is an intravesical solution containing valrubicin, an anthracycline chemotherapy agent administered directly into the bladder. It is indicated for the treatment of non-muscle invasive bladder cancer, particularly in patients with carcinoma in situ who are unresponsive to or intolerant of BCG therapy. The drug works by direct cytotoxic activity against bladder cancer cells.
LOE Approaching
Moderate competitive pressure (30/100) indicates a niche but contested market; LOE approaching suggests downsizing or transition planning for brand teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Valstar Preservative Free offers minimal career growth opportunity; zero linked job postings and approaching LOE indicate a contracting product line with limited promotional spend and team expansion. This role suits experienced professionals managing declining franchises or transitioning to newer oncology launches.
Regional Sales ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.